anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This paper investigates the intriguing relationship between peptic ulcers and hemolysis, 2 seemingly distinct medical conditions, aiming to unravel their potential interconnections and clinical implications. While traditionally studied in isolation, recent evidence has surfaced suggesting possible links and shared mechanisms between these conditions. This paper explores the underlying pathophysiological associations, shared risk factors, diagnostic challenges, management strategies, and implications for clinical practice and health policy. The interplay between peptic ulcers and hemolysis stems from shared inflammatory pathways, notably attributed to Helicobacter pylori infection in peptic ulcers, which might trigger systemic inflammatory responses contributing to hemolysis. Common risk factors including genetic predispositions, autoimmune disorders, and medication use (such as nonsteroidal anti-inflammatory drugs) are implicated in the development of both peptic ulcers and hemolytic conditions, suggesting a potential convergence of these disorders in affected individuals. Diagnostic considerations pose challenges, as overlapping symptoms and laboratory findings may complicate accurate differentiation between peptic ulcers and hemolysis. Recognizing the potential interplay between peptic ulcers and hemolysis holds significant implications for clinical practice and health policy. Streamlining diagnostic algorithms, fostering interdisciplinary collaborations, and developing tailored guidelines are pivotal in optimizing patient care. Continued research efforts, collaborative clinical approaches, and informed health policies are essential in advancing our understanding and enhancing patient care for individuals navigating the intersection of peptic ulcers and hemolysis.
Gastric cancer (GC) remains a leading cause of cancer-related mortality globally. This is due to the fact that majority of the cases of GC are diagnosed at an advanced stage when the treatment options are limited and prognosis is poor. The diffuse subtype of gastric cancer (DGC) under Lauren's classification is more aggressive and usually occurs in younger patients than the intestinal subtype. The concept of personalized medicine is leading to the identification of multiple biomarkers in a large variety of cancers using different combinations of omics technologies. Proteomic changes including post-translational modifications are crucial in oncogenesis. We analyzed the phosphoproteome of DGC by using paired fresh frozen tumor and adjacent normal tissue from five patients diagnosed with DGC. We found proteins involved in the epithelial-to-mesenchymal transition (EMT), c-MYC pathway, and semaphorin pathways to be differentially phosphorylated in DGC tissues. We identified three kinases, namely, bromodomain adjacent to the zinc finger domain 1B (BAZ1B), WNK lysine-deficient protein kinase 1 (WNK1), and myosin light-chain kinase (MLCK) to be hyperphosphorylated, and one kinase, AP2-associated protein kinase 1 (AAK1), to be hypophosphorylated. LMNA hyperphosphorylation at serine 392 (S392) was demonstrated in DGC using immunohistochemistry. Importantly, we have detected heparin-binding growth factor (HDGF), heat shock protein 90 (HSP90), and FTH1 as potential therapeutic targets in DGC, as drugs targeting these proteins are currently under investigation in clinical trials. Although these new findings need to be replicated in larger study samples, they advance our understanding of signaling alterations in DGC, which could lead to potentially novel actionable targets in GC.
BACKGROUND: We have reported that a prehospital 12-lead electrocardiography system (P-ECG) contributed to transport of suspected acute coronary syndrome (ACS) patients to appropriate institutes and in this study, we compared its usefulness between urban and rural areas, and between weekday daytime and weekday nighttime/holiday.
METHODS AND RESULTS: Consecutive STEMI patients who underwent successful primary percutaneous coronary intervention after using P-ECG were assigned to the P-ECG group (n=123; 29 female, 70±13 years), and comparable STEMI patients without using P-ECG were assigned to the conventional group (n=117; 33 females, mean age 70±13 years). There was no significant difference in door-to-reperfusion times between the rural and urban cases (70±32 vs. 69±29 min, P=0.73). Door-to-reperfusion times in the urban P-ECG group were shorter than those in the urban conventional group for weekday nighttime/holiday (65±21 vs. 83±32 min, P=0.0005). However, there was no significance different between groups for weekday daytime. First medical contact to reperfusion time (90±22 vs. 105±37 min, P=0.0091) in the urban P-ECG group were significantly shorter than in the urban conventional groups for weekday nighttime/holiday, but were not significantly different between the groups for weekday daytime.
CONCLUSIONS: P-ECG is useful even in urban areas, especially for patients who develop STEMI during weekday nighttime or while on a holiday.
R. NilamberLal Das, S. Muruhan, R. P. Nagarajan and A. Balupillai, "Naringin Prevents Ultraviolet-B Radiation-induced Oxidative Damage and Inflammation Through Activation of Peroxisome Proliferator-activated Receptor γ in Mouse Embryonic Fibroblast (NIH-3T3) Cells," Journal of Biochemical and Molecular Toxicology 33, no. 3 (2019): e22263, https://doi.org/10.1002/jbt.22263. This Expression of Concern for the above article published online on 4 December 2018 in Wiley Online Library (wileyonlinelibrary.com), has been published by agreement between the journal Editor-in-Chief, Hari K. Bhat; and Wiley Periodicals, Inc. The Expression of Concern has been agreed following concerns raised by a third party regarding the standard deviations presented in Table 2, which are unusually low and show an unexpected even distribution. The authors admitted they made a mistake and wished to correct Table 2. However, since the new data provided could not be substantiated, the editors did not consider the data appropriate to correct the article. The editors would like to issue an Expression of Concern to alert the readers.
This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid cannabidiol (CBD; Epidiolex; oral) to the FDA-approved opioid hydromorphone (Dilaudid; oral) would change the experience of hydromorphone as rated by laboratory measures of pain, subjective reports of drug effects, and cognitive performance. Subjects are healthy individuals with no history of drug use disorder. Study subjects and staff were completed blinded to the study drugs and the class of drugs under investigation and were informed that subjects may receive opioids, stimulants, cannabinoids, benzodiazepines, over the counter medications, and/or placebo. All participants completed all sessions. Sessions lasted up to 8-hours and were conducted at least 7 days apart on an outpatient basis. Primary outcomes were collected from participants prior to dosing and at several hour periods post-dosing.
Risk Summary

There are no adequate data on the developmental risk associated with the use of NUEDEXTA in pregnant women. In oral studies conducted in rats and rabbits, a combination of dextromethorphan/quinidine demonstrated developmental toxicity, including teratogenicity (rabbits) and embryo lethality, when given to pregnant animals (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Data

Animal Data

When dextromethorphan/quinidine was administered orally (0/0, 5/100, 15/100, and 50/100 mg/kg/day) to pregnant rats during the period of organogenesis, embryo-fetal deaths were observed at the highest dose tested and reduced skeletal ossification was observed at all doses. The lowest dose tested (5/100 mg/kg/day) is approximately 1/50 times the recommended human dose (RHD) of 40/20 mg/day on a mg/m2 basis. Oral administration to pregnant rabbits during organogenesis in two separate studies (0/0, 5/60, 15/60, and 30/60 mg/kg/day; 0/0, 5/100, 15/100, and 50/100 mg/kg/day) resulted in an increased incidence of fetal malformations at all but the lowest dose tested. The no-effect dose (5/100 mg/kg/day) is approximately 2/100 times the RHD on a mg/m2 basis.

When dextromethorphan/quinidine was orally administered to female rats during pregnancy and lactation in two separate studies (0/0, 5/100, 15/100, and 30/100 mg/kg/day; 0/0, 5/100, 15/100, and 50/100 mg/kg/day), pup survival and pup weight were decreased at all doses, and developmental delay was observed in offspring at the mid and high doses. A no-effect dose for adverse developmental effects was not identified. The lowest dose tested (5/100 mg/kg/day) is approximately 1/50 times the RHD on a mg/m2 basis.

When dextromethorphan/quinidine was orally administered (0/0, 5/50, 15/50, 25/50 mg/kg) to male and female rats on Postnatal Day 7, the highest dose resulted in neuronal death in brain (thalamus and medulla oblongata). Postnatal Day 7 in rat corresponds to the third trimester of the gestation through the first several months of life but may extend to approximately three years of age in humans.
Bacterial leaf streak caused by Xanthomonas oryzae pv. oryzicola (Xoc) is a continuous threat to rice cultivation, leading to substantial yield losses with socioeconomic implications. Iron ions are essential mineral nutrients for plant growth, but little information is available on how they influence mechanisms of rice immunity against Xoc. Here, we investigated the role of the myeloblastosis-related (MYB) transcriptional repressor OsMYBxoc1 in modulation of rice resistance through control of iron ion transport. Overexpression of OsMYBxoc1 significantly increased rice resistance, whereas OsMYBxoc1 RNA-interference lines and knockout mutants showed the opposite result. Suppression of OsMYBxoc1 expression dampened the immune response induced by pathogen-associated molecular patterns. We demonstrated that OsMYBxoc1 binds specifically to the OsNRAMP5 promoter and represses transcription of OsNRAMP5. OsNRAMP5, a negative regulator of rice resistance to bacterial leaf streak, possesses metal ion transport activity, and inhibition of OsMYBxoc1 expression increased the iron ion content in rice. Activity of the ion-dependent H2O2 scavenging enzyme catalase was increased in plants with suppressed expression of OsMYBxoc1 or overexpression of OsNRAMP5. We found that iron ions promoted Xoc infection and interfered with the production of reactive oxygen species induced by Xoc. The type III effector XopAK directly inhibited OsMYBxoc1 transcription, indicating that the pathogen may promote its own proliferation by relieving restriction of iron ion transport in plants. In addition, iron complemented the pathogenicity defects of the RS105_ΔXopAK mutant strain, further confirming that iron utilization by Xoc may be dependent upon XopAK. In conclusion, our study reveals a novel mechanism by which OsMYBxoc1 modulates rice resistance by regulating iron accumulation and demonstrates that Xoc can accumulate iron ions by secreting the effector XopAK to promote its own infection.
BACKGROUND: Pancreatic surgery remains associated with high morbidity rates. Although postoperative mortality appears to have improved with specialization, the outcomes reported in the literature reflect the activity of highly specialized centres. The aim of this study was to evaluate the outcomes following pancreatic surgery worldwide.
METHODS: This was an international, prospective, multicentre, cross-sectional snapshot study of consecutive patients undergoing pancreatic operations worldwide in a 3-month interval in 2021. The primary outcome was postoperative mortality within 90 days of surgery. Multivariable logistic regression was used to explore relationships with Human Development Index (HDI) and other parameters.
RESULTS: A total of 4223 patients from 67 countries were analysed. A complication of any severity was detected in 68.7 per cent of patients (2901 of 4223). Major complication rates (Clavien-Dindo grade at least IIIa) were 24, 18, and 27 per cent, and mortality rates were 10, 5, and 5 per cent in low-to-middle-, high-, and very high-HDI countries respectively. The 90-day postoperative mortality rate was 5.4 per cent (229 of 4223) overall, but was significantly higher in the low-to-middle-HDI group (adjusted OR 2.88, 95 per cent c.i. 1.80 to 4.48). The overall failure-to-rescue rate was 21 per cent; however, it was 41 per cent in low-to-middle- compared with 19 per cent in very high-HDI countries.
CONCLUSION: Excess mortality in low-to-middle-HDI countries could be attributable to failure to rescue of patients from severe complications. The authors call for a collaborative response from international and regional associations of pancreatic surgeons to address management related to death from postoperative complications to tackle the global disparities in the outcomes of pancreatic surgery (NCT04652271; ISRCTN95140761).
Pulmonary arterial hypertension (PAH) is a devastatig disease with high mortality. Familial cases of PAH are usually characterized by autosomal dominant transmission with reduced penetrance, and mutations in Bone Morphogenetic Protein receptor type 2 (BMPR2), account for approximately 70% of familial cases, but some familial cases are of unknown genetic etiology. A novel heterozygous missense variant c.608 G>A, G203D in the KCNK3 (potassium channel subfamily K, member 3) gene was identified as a disease causing candidate gene in the family. Five additional heterozygous missense variants were independently identified in 92 unrelated familial PAH and 230 idiopathic PAH patients, genetically independently confirming the results in the first family. All six novel variants were located in highly conserved domains and were predicted to be damaging. Electrophysiological studies of the channel indicated that these missense mutations all result in loss of function, and some mutations were rescued by the phospholipase inhibitor ONO RS-082.
Systems and methods are provided to manage inventory of products used in health care practices and organizations. The systems include tools to track inventory, purchase inventory and to predict how much inventory will be used. The method includes obtaining a schedule of future health care procedures. The method predicts an amount of a product that will be consumed by comparing each procedure against a corresponding procedure profile obtained from a procedure profile database. Each procedure profile includes product usage information of products expected to be consumed in a given procedure. This information is then used to predict when orders for replacement units of the product should be placed, to prevent insufficient supply of the product for a scheduled procedure. A graphical user interface is presented to order the replacement units by a determined date and for a determined quantity. Vendors interact with the system to sell the products.
The invention discloses a traditional Chinese medicine formula for treating scapulohumeral periarthritis. The traditional Chinese medicine formula comprises angelica sinensis, asarum sieboldii, philippine flemingia root, cassia twig, radix aconiti preparata, radix achyranthis bidentatae, frankincense, radix angelicae, rhizoma drynariae, white atractylodes rhizome, licorice root, rhizoma cibotii, the root of fangji, notopterygium root, safflower carthamus, fennel, astragalus membranaceus, caulis spatholobi, lalang grass rhizome, lucid ganoderma, radix clematidis and pseudo-ginseng. The traditional Chinese medicine formula is obvious in treatment effect and is capable of treating both symptoms and root causes; and the relapse of the scapulohumeral periarthritis is avoided as long as the scapulohumeral periarthritis is cured. In addition, the traditional Chinese medicine formula is easy in raw material obtainment, convenient to take, relatively short in treatment course, low in cost and good in comprehensive effect. The effective rate of the traditional Chinese medicine formula for treating the scapulohumeral periarthritis reaches 98%; and the cure rate of the scapulohumeral periarthritis reaches 90%. Meanwhile, the traditional Chinese medicine formula has good prevention and auxiliary treatment functions to soft tissue damage related diseases.
Chronic idiopathic urticaria is thought to affect approximately 0.1% of the population. It can be very disabling and difficult to treat. Antihistamines are the only drugs licensed for treatment of urticaria, however there is a group of severely affected patients with chronic idiopathic urticaria who fail to respond. Previous trials have shown ciclosporin to be beneficial, and small studies support the use of intravenous immunoglobulins and plasmapheresis. However, not only are these options expensive, but since chronic idiopathic urticaria may persist for years, their prolonged use may be limited by adverse effects. We have previously published a report of 2 patients who responded to methotrexate, and wish to properly evaluate the efficacy of methotrexate in the treatment of CIU.

In the first part of the study patients will be given either placebo or methotrexate for 8 weeks and in the second part of the study, non-responders will be offered open labelled methotrexate for 8 weeks.
A method for providing cloud-based communication for blood bank collection and management is provided. The method may include detecting and registering a plurality of cloud systems. The method may further include enabling cloud communications for the plurality of cloud systems. Additionally, the method may include receiving at least one blood donation request and blood donation event using the plurality of cloud communications for the plurality of cloud systems. The method may also include recommending and generating lists of blood donors based on the at least one blood donation request and the plurality of cloud systems. The method may further include presenting to users associated with the plurality of cloud systems the at least one blood donation request and blood donation event using the plurality of cloud communications, wherein the users associated with the plurality of cloud systems are based on the plurality of lists of blood donors.
Patients should be informed of the following information to aid in the safe and effective use of LEVOTHROID®:

  1. Notify your physician if you are allergic to any foods or medicines, are pregnant or intend to become pregnant, are breast-feeding or are taking any other medications, including prescription and over-the-counter preparations.
  2. Notify your physician of any other medical conditions you may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems. Your dose of medications used to control these other conditions may need to be adjusted while you are taking LEVOTHROID®. If you have diabetes, monitor your blood and/or urinary glucose levels as directed by your physician and immediately report any changes to your physician. If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently.
  3. Use LEVOTHROID® only as prescribed by your physician. Do not discontinue or change the amount you take or how often you take it, unless directed to do so by your physician.
  4. The levothyroxine in LEVOTHROID® is intended to replace a hormone that is normally produced by your thyroid gland. Generally, replacement therapy is to be taken for life, except in cases of transient hypothyroidism, which is usually associated with an inflammation of the thyroid gland (thyroiditis).
  5. Take LEVOTHROID® as a single dose, preferably on an empty stomach, one-half to one hour before breakfast. Levothyroxine absorption is increased on an empty stomach.
  6. It may take several weeks before you notice an improvement in your symptoms.
  7. Notify your physician if you experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
  8. Notify your physician if you become pregnant while taking LEVOTHROID®. It is likely that your dose of LEVOTHROID® will need to be increased while you are pregnant.
  9. Notify your physician or dentist that you are taking LEVOTHROID® prior to any surgery.
  10. Partial hair loss may occur rarely during the first few months of LEVOTHROID® therapy, but this is usually temporary.
  11. LEVOTHROID® should not be used as a primary or adjunctive therapy in a weight control program.
  12. Keep LEVOTHROID® out of the reach of children. Store LEVOTHROID® away from heat, moisture, and light.
  13. Agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium tablets should not be administered within 4 hrs of these agents.
To return support information to a user of an inspection order source by automatically generating appropriate support information according to an inspection order.SOLUTION: According to an embodiment, a medical information processing system includes an acquisition part, a first generation part, an analysis part, a second generation part, and a display control part. The acquisition part acquires medical data related to a first object of a patient according to an inspection order. The first generation part generates first support information for supporting diagnosis of the first object on the basis of the medical data. The analysis part analyzes a second object different from the first object on the basis of the medical data. The second generation part generates second support information for supporting diagnosis of the second object on the basis of an analysis result of the second object. The display control part displays at least the second support information out of the first support information and the second support information in a display part.SELECTED DRAWING: Figure 2
The invention discloses an atenolol injection. The atenolol injection is prepared from atenolol and pharmaceutically acceptable auxiliary materials, and the concentration of the atenolol injection is 0.45-0.55mg/mL according to the concentration of atenolol. The auxiliary materials comprise the following components: a composite solvent consisting of 1,2-propylene glycol and water, a buffer system consisting of sodium dihydrogen phosphate and disodium hydrogen phosphate, sodium chloride which is taken as an osmotic pressure regulator, and sodium edetate which is taken as a metal ion complexing agent, wherein in the composite solvent, the volume percentage of 1,2-propylene glycol accounts for 10-35%. The invention also discloses a preparation method of the atenolol injection. By adopting a mode of adding carbon twice, the purpose of adsorbing pyrogen in the injection can be achieved, and a main medicine of a solution cannot be significantly adsorbed. The atenolol injection prepared by adopting the method disclosed by the invention is good in stability and safe and effective in clinical use.